Calimmune's HIV Clinical Trial and the California Stem Cell Agency: Decisions Looming on the State-backed Research
The HIV clinical trial involving Calimmune and the California stem cell agency appears to be headed today for several major decision points following the purchase of the company in a deal that could total more than $400 million.
CSL Behring announced yesterday that it was acquiring the company. One published report said that CSL was not interested in th…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.